XML 66 R74.htm IDEA: XBRL DOCUMENT v3.20.1
Note 14 - License, Collaboration and Distribution Agreements (Details Textual) - USD ($)
1 Months Ended 2 Months Ended 12 Months Ended
Jun. 01, 2013
Feb. 07, 2012
Apr. 30, 2013
Jan. 31, 2013
Oct. 31, 2012
Sep. 30, 2012
Jan. 31, 2012
Oct. 31, 2012
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2014
Contract with Customer, Liability, Total                 $ 41,000      
Revenue from Contract with Customer, Including Assessed Tax                 $ 6,599,000 $ 12,508,000 $ 18,230,000  
Partner Pharmacies [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]                        
Concentration Risk, Percentage                 21.00% 1.00% 0.00%  
Reallocated from Deferred Revenue [Member]                        
Stockholders' Equity, Period Increase (Decrease), Total               $ 600,000        
Avenova Product [Member]                        
Revenue from Contract with Customer, Including Assessed Tax                 $ 1,000,000      
China Pioneer [Member]                        
Proceeds from Issuance or Sale of Equity, Total           $ 2,500,000            
Unit Purchase Agreement Shares Per Unit           1            
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right           1            
Excess Fair Value Over Proceeds Received From Purchase               $ 1,000,000        
China Pioneer [Member] | Tranche One [Member]                        
Purchase Agreement Units           800,000            
China Pioneer [Member] | Tranche Two [Member]                        
Purchase Agreement Units         1,200,000              
Purchase Agreement Unit Price Per Share         $ 1.25              
Purchase Unit Agreement Total Units Fair Value         $ 3,500,000              
China Pioneer [Member] | Neutrophase [Member]                        
Proceeds from Collaborators       $ 312,500     $ 312,500         $ 625,000
Maximum Possible Sales Discounts           $ 500,000            
Integrated Healing Technologies, LLC [Member] | Neutrophase [Member]                        
Proceeds from Collaborators   $ 750,000                    
Virbac [Member] | Auriclosene (NVC-422) [Member]                        
Proceeds from Collaborators     $ 250,000                  
Principal Business Enterprise, Inc. [Member] | Neutrophase [Member]                        
Proceeds from Collaborators $ 200,000                      
China Pioneer and Principal Business Enterprise Inc. [Member] | Samples and Future Products [Member]                        
Contract with Customer, Liability, Revenue Recognized                   $ 41,000    
McKesson Corporation [Member] | Avenova Product [Member]                        
Contract with Customer, Liability, Revenue Recognized                 4,600,000 11,000,000 $ 13,600,000  
McKesson Corporation [Member] | Avenova Product [Member] | Accounts Payable and Accrued Liabilities [Member]                        
Contract with Customer, Liability, Total                 400,000 1,400,000    
McKesson Corporation [Member] | Avenova Product [Member] | Prepaid Expenses and Other Current Assets [Member]                        
Contract with Customer, Rebate Liability, Current                 $ 400,000 $ 900,000